# Injectable Nanobody Wins FDA Approval for Myasthenia Gravis

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/neurology/generalneurology/123885) · 2026-11-13 · Medicine
Page: https://themorning.science/story/injectable-nanobody-wins-fda-approval-for-myasthenia-gravis-6c01f6fabb898f2c
Kind: launch · Impact: medium

## In brief

- The FDA approved injectable gefurulimab (brand name Klygefa) for generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.
- Gefurulimab is a dual-binding nanobody that blocks activation of complement component 5 (C5).
- MedPage Today reported the approval on 2026-11-13.

## Why it matters

It adds a new injectable C5-blocking treatment option for a subset of adults with generalized myasthenia gravis, a neuromuscular autoimmune disease.

## Timeline

- 2026-11-13: FDA approved gefurulimab (Klygefa) for generalized myasthenia gravis in anti-AChR antibody-positive adults

## Coverage

- [Injectable Nanobody Wins FDA Approval for Myasthenia Gravis](https://www.medpagetoday.com/neurology/generalneurology/123885) — MedPageToday.com - medical news for physicians, 2026-11-13

Tags: myasthenia gravis, nanobody, complement inhibitor, fda approval, neurology, drug approval

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science